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Abstract
Background: In people with cystic fibrosis infection with NonTuberculous Mycobacteria is of increasing prevalence.
Mycobacterium abscessus complex is of particular concern and has been associated with adverse clinical outcomes.
Optimal treatment usually requires multiple antibiotics for over 12 months. When considering lung transplantation
for patients with NonTuberculous Mycobacteria potential benefits must be balanced against the risks of
uncontrolled infection post-transplant and significant side-effects associated with treatment. In this survey we
assessed current international practice with regard to assessing and listing patients for lung transplantation.
Methods: We designed a questionnaire enquiring about local practice regarding screening for NonTuberculous
Mycobacteria infection, specific contra-indications to transplantation, management and segregation of patients
pre- and post-transplant. The survey was sent via e-mail to 37 paediatric and adult lung transplant centres across
Europe, North America and Australia.
Results: We gathered complete questionnaires from 21 centres (57% response rate). Few centres (29%) have a clear
written policy regarding NonTuberculous Mycobacteria. Sixteen (76%) centres require molecular identification of
NonTuberculous Mycobacteria species. Only four centres would consider infection with M. abscessus complex in
itself a contra-indication for listing, however 76% regard it as a relative contra-indication. Eighty-six percent require
treatment pre-transplantation. Finally, only 61% of centres had a clear policy regarding segration of patients
pre-transplant and 48% post-transplant.
Conclusions: The issue of NonTuberculous Mycobacteria infection in people with cystic fibrosis requiring lung
transplantation is well-recognized however current international recommendations are not detailed and there is
variation in practice between centres. There is an urgent requirement for high quality clinical data to inform
decision-making.
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Background
Pulmonary infection with nontuberculous mycobacteria
(NTM) in people with cystic fibrosis (CF) is of increas-
ing importance and concern to both patients and clini-
cians [1]. Infection with NTM is of particular relevance
during the assessment process of suitability for lung
transplantation [2].
The incidence of respiratory cultures positive for
NTM in people with CF has risen over recent decades
[3]. Multicenter studies have reported varying prevalence
that ranges from 2.7% across Europe [4], 6.6% in France
[5] to 14% throughout the United States (US) [6]. Sig-
nificant geographical variation has also been identified,
for example in the US some states have been found to
have a prevalence as high as 20% whereas in others it is
much lower at < 5% [6]. Environmental factors are
thought to influence this variation but screening prac-
tices may also vary between individual CF centres. The
most common NTM species isolated from people with
CF are Mycobacterium abscessus complex and M. avium
complex (MAC).
The American Thoracic Society/Infectious Disease
Society of America definition of NTM pulmonary
disease (NTM PD) involves clinical, radiological and
microbiological criteria and is widely used clinically [7].
Importantly, pulmonary infection with M. abscessus
complex in people with CF has been associated with
accelerated decline in lung function and is of particular
clinical concern [4, 8–10]. There is also emerging
evidence to suggest transmission of M. abscessus com-
plex between individuals with CF [11, 12]. NTM PD is
challenging to treat requiring multiple antibiotic regimes
for a prolonged period of at least 12 months [13, 14].
The antibiotics used are frequently associated with
adverse effects and represent a significant treatment
burden for patients. Ultimately NTM are also often
difficult to eradicate from the airways of people with
CF despite treatment.
In the past pulmonary NTM infection in patients with
CF was considered an absolute contra-indication for lung
transplantation by some groups due to poor post-
transplant outcomes that were largely attributed to uncon-
trolled infection in the context of systemic immunosup-
pression, though the ISHLT guidelines never endorsed
NTM infection as an absolute contraindication [15–17].
Soft tissue and wound infections are often particularly
challenging to treat post-operatively [18]. Specifically, the
presence of M. abscessus complex pre-transplant has been
associated with severe clinical problems and poor out-
comes following lung transplantation [15–17]. The spe-
cific subspecies of M. abscessus complex may also impact
on risk stratification [19]. The isolation of NTM in re-
spiratory samples post-lung transplantation has also been
associated with adverse clinical outcomes [18, 20].
However, some single-centre case series have sug-
gested that lung transplantation in people with NTM in-
fection can be associated with comparable outcomes to
those free of NTM infection [21–23]. Albeit with the
caveat that anti-NTM treatment is likely to need to be
prolonged and may be associated with adverse effects
and complications.
The 2014 update for the selection of lung transplant
candidates from the International Society for Heart and
Lung Transplantation (ISHLT) recommends “controlled
chronic infection pre-operatively and a reasonable ex-
pectation for adequate control post-operatively” in order
for patients with NTM to be safely listed for transplant-
ation [24]. Recent consensus recommendations from the
United States Cystic Fibrosis Foundation (CFF) and the
European Cystic Fibrosis Society (ECFS) emphasize the
need to thoroughly evaluate patients with CF for NTM
as part of the lung transplant assessment process and to
start treatment prior to transplant listing but largely
leave decision-making open to the individual centre and
clinician [14].
The increasing prevalence of NTM in people with CF
means that it is becoming more and more of an issue
during the process of assessment of suitability for lung
transplantation [2]. Anecdotally we have observed differ-
ent approaches in the global lung transplantation com-
munity towards this challenging clinical area and we
therefore wished to investigate current practice world-
wide with regard to assessing and listing patients for
lung transplantation with CF who have NTM infection.
Methods
We designed a survey consisting of 16 questions enquiring
about local practice regarding screening for NTM
infection, specific contra-indications to transplantation,
management and segregation of patients pre- and post-
transplant (Fig. 1). This questionnaire was sent via e-mail
to 37 adult and pediatric lung transplantation centres
across Europe, North America and Australia in April 2016.
Results
We received complete questionnaires from 21 centres
(57% response rate).
Screening for NTM during transplant assessment process
All centres specifically screened patients with CF for
NTM infection pre-transplant but only a minority (29%)
had a clear written policy regarding this issue (Table 1).
Sixteen centres (76%) required molecular identification
of NTM species. The main respiratory samples (Fig. 1)
accepted as relevant were sputum and broncho-alveolar
lavage (100 and 95% respectively). Induced sputum was
also considered acceptable by 16 centres. Only one
centre based decisions on results from cough swabs.
Tissot et al. BMC Pulmonary Medicine  (2018) 18:86 Page 2 of 5
Policies for suitability of patients with NTM for lung
transplantation listing
Only four centers considered infection with M. abscessus
complex in itself an absolute contra-indication for trans-
plant listing (Fig. 2). More than half (57%) stated they
would not list a patient with persisting positive res-
piratory cultures despite optimal treatment. A majority
(76%) of centres considered persistent M. abscessus
complex infection to be a relative contraindication to
listing if other adverse factors are present. Eighteen
centres require treatment pre-transplant and 20 (95%)
would decide a peri-transplant treatment cocktail at the
time of listing.
Infection control policies
Finally, 13, centres (61%) apply a segregation policy
based on NTM status of patients pre-transplant and
10 (48%) post-transplantation, for example in outpatient
clinic waiting areas.
Discussion
This survey captures current practice in the global lung
transplant community with regard to patients with CF
and NTM infection. This is well recognised to be a chal-
lenging issue clinically with a dearth of high quality evi-
dence on which to base decision-making. Most centres
do currently consider patients with CF and NTM infec-
tion for lung transplantation assessment and potential
listing, i.e. it is not considered an absolute contraindica-
tion. However, the majority do consider it a relative
contraindication if other comorbidities or relative con-
traindications are present. The specific species of NTM
and response to treatment pre-transplant are also taken
in to account during the decision-making process at the
majority of centres.
In our questionnaire, we asked about isolation of NTM
from respiratory samples, i.e. infection rather than pa-
tients who fulfil the ATS NTMPD criteria per se. This was
because the presence alone of NTM, and M. abscessus
complex in particular, is a significant potential concern in
Table 1 Questionnaire results (n = 21 centres)
Question Yes n (%)
Do you have a clear written policy regarding the
assessment and listing of patients with CF and NTM
infection?
6 (29)
During assessment do you require screening for NTM? 21 (100)
Do you require molecular identification of NTM
species?
16 (76)
Do you regard current infection with MAC an absolute
contraindication?
1 (5)
Do you regard current infection with M. abscessus
complex as an absolute contraindication?
4 (19)
Do you regard persisting MAC or M. abscessus complex
infection despite optimal therapy as an absolute
contraindication?
12 (57)
Would you regard a patient with persisting M.
abscessus complex and another relative
contraindication as together representing an absolute
contraindication?
16 (76)
Do you require specific NTM treatment to be
undertaken before listing?
18 (86)
At time of listing is a treatment cocktail decided on for
use peri-transplant?
20 (95)
Are patients segregated on the basis of NTM status
pre-transplant?
13 (62)
Are patients segregated post-transplant on the basis of
NTM status?
10 (48)
Abbreviations: CF Cystic Fibrosis, NTM NonTuberculous Mycobacteria,
MAC Mycobacterium avium Complex, M. abscessus complex Mycobacteria
abscessus complex
Fig. 2 What is considered a contraindication to lung transplantation at
each centre? Total number of centres returning questionnaires = 21.
In answer to the question, “are the following considered an absolute
contraindication for lung transplantation?”: MAC: current infection
with Mycobacterium avium Complex; MABC: current infection with
Mycobacterium abscessus complex; Persistent culture: persisting MAC
or M. abscessus complex infection despite optimal therapy; other CI:
Would you regard a patient with persisting M. abscessus complex
and another relative contraindication as together representing an
absolute contraindication?
Fig. 1 Type of respiratory samples considered as relevant for NTM
screening at assessment for lung transplantation. Total number of
centres returning questionnaires = 21. Answers to the question:
“Do you consider the following respiratory samples as relevant for
NTM screening?”. BAL: bronchio-alveolar lavage
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the context of immunosuppression post-major thoracic
surgery as is the case following lung transplantation.
Our findings highlight the importance of further high-
quality clinical research to comprehensively investigate
the outcomes and international experience of patients
with NTM after lung transplantation. Other key ques-
tions include risk stratification around specific species
and subspecies, resistance profiles, response to treatment
and disease-burden pre-transplant. For example, In a
single centre paediatric case series adverse outcomes
were associated with infection pre-transplant with M.
abscessus subspecies abscessus with improved results in
children with M. abscessus subspecies bolletti or massil-
liense infection [19]. M. avium complex is the most preva-
lent grouping of NTM in North American patients with
CF and data is equally lacking around outcomes and best
practice in individuals with M.avium complex infection.
The variation in international practice that we have
identified affirms the current attention being given to
NTM infection in respiratory disease and CF in particu-
lar. As a poorly-defined strong relative contraindication
to lung transplantation NTM and M. abscessus complex
status in particular is of huge relevance to individual pa-
tients in terms of lung transplantation listing being a vi-
able option or not for them, which may be life-changing.
Evidence to support an increasing prevalence of NTM in
people with CF continues to grow. The proportion of pa-
tients affected and the complexity of treatment necessary
in terms of length, toxicity and limited efficacy make in-
fection with NTM an issue of major concern for CF cli-
nicians. The specific question of considering lung
transplantation for these patients adds a further level of
complexity with the added post-transplant threat of
systemic immunosuppression and increased risk of
drug-related toxicity.
It is clear in both the ISHLT and the CFF/ECFS con-
sensus recommendations that NTM infection has to be
looked for and if possible treated pre-transplant. The
ISHLT stated that “chronic infection with highly virulent
and/or resistant microbes that are poorly controlled pre-
transplant” is an absolute contraindication, which is a
situation that can been seen in NTM infection. In the
CFF/ECFS document it is recommended that “the
presence of persistent MABC or MAC infection despite
optimal therapy is not an absolute contraindication for
lung transplant referral”. Pragmatically therefore many
transplant clinicians firstly evaluate the “controlled”
character of the chronic infection or colonization with
NTM pre-transplant and then evaluate the post-
transplant risk associated with the presence of NTM. It
is interesting to note that almost all centres do not con-
sider in itself the presence of NTM as an absolute
contraindication but a majority would not list a patient
with a failure of an optimal therapy to eradicate NTM
or if associated with another relative contraindication.
This illustrates in our view the central concern of clini-
cians to have an available efficient combination of antibi-
otics that can be tolerated by the patient before moving
on to the difficult process of lung transplantation.
Finally, the relatively low rate of centres segregating pa-
tients depending on NTM status pre- and post-transplant
is concerning when placed in the context of the recent
studies suggesting potential transmission of M. abscessus
complex between patients with CF [11, 12, 25]. Extensive
and elaborate infection control measures have been rec-
ommended to prevent such transmission events [14]. The
likely low number of patients post-transplant with NTM
is also a possible explanation for the lower number of cen-
tres segregating post-transplant [18, 20].
There are some limitations to our work. Firstly, we did
not send the questionnaire to all existing lung trans-
plantation centres. Our objective was not to be exhaust-
ive but to have a representative sample as in an opinion
poll. Secondly, we did not adjust the results for the size
of centre, which means an answer from a small centre,
for example performing less than 20 transplants per year,
has the same value as that from a larger centre.
Conclusions
In conclusion, the issue of NTM infection in patients
with CF requiring lung transplantation is of current ex-
tensive debate and discussion amongst the lung trans-
plantation community. Although many clinicians
anecdotally suspected sub-optimal outcomes following
transplantation in patients with NTM, most centres do
not consider it as an absolute contra-indication unless
associated with other comorbidities or in the absence of
a suitable cocktail for antimicrobial therapy. Practice is
not consistent however between centres and there is an
urgent requirement for the collection and analysis of
high-quality clinical data followed by development of an
evidence-based guideline on this specific issue.
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